Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?
about
Oral budesonide for induction of remission in ulcerative colitisInflammatory bowel disease: an expanding global health problemIntegrin antagonists are effective and safe for Crohn's disease: a meta-analysisLong-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity.Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysisLong-term safety and efficacy of budesonide in the treatment of ulcerative colitisPharmacological reversion of sphingomyelin-induced dendritic spine anomalies in a Niemann Pick disease type A mouse model.Autophagy: a new target or an old strategy for the treatment of Crohn's disease?Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives.The role of mucosal healing in the treatment of patients with inflammatory bowel diseaseThe financial impact of a nurse-led telemedicine service for inflammatory bowel disease in a large district general hospital.Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology.Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis.Improvement of side-effects and treatment on the experimental colitis in mice of a resin microcapsule-loading hydrocortisone sodium succinate.Investigation of the colon-targeting, improvement on the side-effects and therapy on the experimental colitis in mouse of a resin microcapsule loading dexamethasone sodium phosphate.Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.Tumor necrosis factor-α and oral inflammation in patients with Crohn disease.
P2860
Q24186368-F1C52A00-0347-431E-899C-7AA241888836Q33608406-2BD14DA0-D92F-4239-9BEA-E2BCFE75CF00Q35473311-C3883E60-DC9C-4F80-894F-B2AFBB13FDE0Q36426949-1E48AFD7-5411-4712-BCA4-FDE66DBFF63DQ36659176-B8E79175-CBED-4732-B205-3DF6A9172D2BQ37162504-88E0E6DE-0F16-4F27-AC82-34F4CE9FDFE4Q37577773-E1119E6C-C907-44EF-A511-097B2626B163Q37644390-FB6F2CC5-986A-4937-88DA-DBEA2D7BCBBEQ38099513-BC8C379D-C27B-47C9-90E5-847A80086D93Q38112106-F4D970C9-9F9A-4F27-BF18-504834C880FDQ38176299-94DC433D-420B-4AFC-A91A-E1B4A9FB3BB8Q38608958-F00E2152-2874-4453-850F-3F8988D35DFEQ39251794-70BC7E0E-BF1D-4C67-8A91-849EBCAF0C40Q42695145-9112CC73-C105-442D-8B13-D48068AE0CD6Q47745759-03EFE9BC-86AE-45AE-89D3-7FDC555A01C9Q51074798-3116E939-5780-4CD8-8E67-A67A19590218Q53493579-561177B9-CE71-4A2E-846F-A16B65777564Q53783957-1E865F8D-8DC5-454E-9565-94A7752635BCQ54215809-C36C66A4-1440-4381-AB5E-F0363B1F6CC9
P2860
Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Second-generation corticostero ...... fective and less side effects?
@en
type
label
Second-generation corticostero ...... fective and less side effects?
@en
prefLabel
Second-generation corticostero ...... fective and less side effects?
@en
P2860
P356
P1433
P1476
Second-generation corticostero ...... fective and less side effects?
@en
P2093
Chiara De Cassan
Silvio Danese
P2860
P304
P356
10.1159/000338128
P577
2012-07-12T00:00:00Z